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Abstract
This paper presents a systematic literature review with respect to application of data science and machine learning (ML) to
heart failure (HF) datasets with the intention of generating both a synthesis of relevant findings and a critical evaluation of
approaches, applicability and accuracy in order to inform future work within this field. This paper has a particular intention
to consider ways in which the low uptake of ML techniques within clinical practice could be resolved. Literature searches
were performed on Scopus (2014-2021), ProQuest and OvidMEDLINE databases (2014-2021). Search terms included ‘heart
failure’ or ‘cardiomyopathy’ and ‘machine learning’, ‘data analytics’, ‘data mining’ or ‘data science’. 81 out of 1688 articles
were included in the review. The majority of studies were retrospective cohort studies. The median size of the patient cohort
across all studies was 1944 (min 46, max 93260). The largest patient samples were used in readmission prediction models
with the median sample size of 5676 (min. 380, max. 93260). Machine learning methods focused on common HF problems:
detection ofHF fromavailable dataset, prediction of hospital readmission following index hospitalization,mortality prediction,
classification and clustering of HF cohorts into subgroups with distinctive features and response to HF treatment. The most
common ML methods used were logistic regression, decision trees, random forest and support vector machines. Information
on validation of models was scarce. Based on the authors’ affiliations, there was a median 3:1 ratio between IT specialists
and clinicians. Over half of studies were co-authored by a collaboration of medical and IT specialists. Approximately 25% of
papers were authored solely by IT specialists who did not seek clinical input in data interpretation. The application of ML to
datasets, in particular clustering methods, enabled the development of classification models assisting in testing the outcomes
of patients with HF. There is, however, a tendency to over-claim the potential usefulness of ML models for clinical practice.
The next body of work that is required for this research discipline is the design of randomised controlled trials (RCTs) with
the use of ML in an intervention arm in order to prospectively validate these algorithms for real-world clinical utility.
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1 Introduction
Cardiovascular disease (CVD) is the leading cause of death in
the United Kingdom (UK) [1] and worldwide [2]. Advances
in pharmacotherapy and invasive strategies have resulted in
the increased survival of patients with acute coronary syn-
dromes (ACS), leading to the increased prevalence of heart
failure (HF) [3,4]. There are approximately 920,000 peo-
ple in the UK living with HF and around 200,000 new HF
diagnoses each year [5]. HF causes approximately 5% of
all emergency adult hospital admissions [6] and it accounts
for approximately 2% of total NHS expenditure [6]. HF is a
complex condition affecting a wide spectrum of the popula-
tion [6] and in order to provide credible characteristics of the
group of patients with HF, a reliable data collection process
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is needed. The introduction and adoption of electronic health
records (EHR) has initiated widespread interest and created
opportunities for translational research with respect to car-
diovascular health data [7]. The healthcare sector generates
30%of the digital dataworldwide [8]. The use of digital clini-
cal data has the potential to transform healthcare systems into
“self-learning health systems” [9,10]. In contrast to clinical
trials, observational cohort studies based on extracts from
digital data and EHR typically do not exclude real-world
patients, such as elderly and frail individuals with multiple
co-morbidities [11]. Research into health data can change
clinical practice and improve patient outcomes, especially
for cohorts of patients who would not have been recruited
to clinical trials. This was exemplified in Sweden, when a
change in antiplatelets prescribing was introduced follow-
ing discoveries from Swedish Heart Registry - SWEDEHeart
[11]. Governments and policymakers increasingly recognise
that the healthcare sector is a field where valuable insights
can now be uncovered through big data analytics [12]. There
are an increasing number of governments that have set out
plans for AI in the healthcare sector [12]. In the UK, a
policy document published in October 2018 set out the gov-
ernment’s vision for the use of technology and digital data
within health and care to meet the needs of all NHS users
[13]. This included a plan that all the healthcare organisa-
tions should have a board-level understanding of how data
and technology can drive their services and strategies. The
document provided the framework for theNHS to take charge
of the digital maturity of its organisations. Collaboration, co-
development and iteration between innovators and the NHS
were set to become the new norm [13]. In an order to fulfil
this requirement, the UK government is funding the Digital
Fellow Programme, which has the aim of providing train-
ing for clinical staff to develop digital skills [14]. Soon after
this policy was made available to the public, the govern-
ment published ‘The Topol Review: Preparing the healthcare
workforce to deliver the digital future’ which sets out the
vision for the NHS in a digital era. The Topol Review, led
by cardiologist, geneticist, and digitalmedicine researcherDr
Eric Topol, explores how to prepare the healthcare workforce
to deliver the digital future through education and training.
Dr Topol appointed a Review Board and three Expert Advi-
sory Panels [15]. The Topol review argues that data analytics
will to be the bread and butter of the future workforce of
the NHS. In the light of the increasing incidence of HF and
a widespread interest in ML application to health data, we
present a literature review of studies usingML to analyse HF
datasets. The aim of this review is to learn howML can com-
plement current clinical practice andmanagement of patients
with HF.
2 Outline of the paper
This systematic literature review is comprised of eight sec-
tions. Section 1, Introduction, outlines the rationale for the
review. Section 3 provides a summary of the previous litera-
ture reviews undertaken in the field of HF and ML. Section
4, Material and Methods, provides the search criteria, scope
notes for the search criteria and inclusion and exclusion crite-
ria. In Sect. 5, Results, we describe the commonHFproblems
addressed by ML in the reviewed papers, general character-
istics of the studies, such as sources of the datasets, sample
size, types of variables used in studies, management of miss-
ing data, ML algorithms used and their performance. This
section considers how gaps in the field have been addressed
in recent years and the impact of ML on the progress of HF
problem solving. In Sect. 6, Discussion, We discuss the role
of predictive models in international HF guidelines. In Sect.
7, Gaps and Research Opportunities, we discuss the direc-
tions for further research in ML and HF, as well as the need
for development of models using modern HF patient cohorts
and the standards for the reporting of studies usingMLandAI
in healthcare data. Section 8, Conclusions, provides a sum-
mary of most important elements of the review and outlines
the limitations of the review.
3 Previous systematic literature reviews on
ML and HF dataset
There are previous systematic reviews presenting studies on
ML and HF datasets. Rahimi et al. (2014) reviewed ML
methods, discrimination, calibration and model validation
methods of studies from 1995 to 2013 [16]. They concluded
that risk prediction models have low uptake amongst clin-
icians [16]. In support of this thesis, they cited the Postal
Survey of Physicians attitudes to implement cardiovascular
prediction rules [17]. Tripolity et al. (2017) reviewed HF
classification models from 2000-2016 [18]. They observed
that in most cases researchers focused on two or three-class
classification problems of HF severity [18] even though eti-
ology and symptoms of HF are more complex and can not be
fully addressed by answering dichotomous questions. Alba
et al. (2013) reviewed the mortality prediction models of
ambulatory patients with HF [19]. They observed that out of
32 studies, only 5 studies (15%) were validated in an inde-
pendent cohort of patients [19]. The lack of validation on
external datasets made it impossible to evaluate how well
the models would generalise in a real-world clinical setting.
Mahajan et al. (2018) reviewed predictive models for identi-
fying the risk of readmission after index hospitalization for
HF and suggested that more work needs to be done for cal-
ibration, external validation, and deployment of predictive
models to ensure suitability for clinical use [20]. Bazoukis
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et al. (2020) included studies using data from heterogeneous
sources - clinical trials, data from cardiopulmonary exercise
stress tests, left ventricular assist device (LVAD) and cardiac
resynchronisation therapy (CRTP) [21]. They performed a
quality assessment of the ML studies using a novel score
proposed by Qiao [22]. They concluded that ‘at the moment
ML could not replace clinical cardiologists’, which was pre-
ceded by disclaimer that analysis of healthcare data with ML
techniques still act as an auxiliary decisional role [21].
4 Methods
4.1 Identification of studies and literature searches
Literature searches were performed in November 2019
and updated in February 2021. This literature review fol-
lows a systematic reviewmethodologywhereby thePRISMA
framework was used to evaluate the suitability of studies for
inclusion within the review. Figure 1 shows the flow dia-
gram of the identification process for articles included in this
review. The initial search identified 2679 articles published
between 1/2014 and 2/2021, of which 1688 studies remained
after removing duplicates. Out of 1688 studies, 1497 were
excluded based on the title and abstract screen. 191 stud-
ies were considered for full text analysis. 110 studies were
excluded during full-text screening. Eighty-one studies met
the inclusion criteria and were included in the qualitative and
quantitative analysis
SCOPUS, ProQuest and MEDLINE Ovid databases were
searched using the following terms - search terms included
(“heart failure”ORcardiomyopathy/iesOR“cardiac oedema”
OR “paroxysmal dyspnoea”) AND (“machine learning” OR
“data mining” OR “data analytics” OR “data science”).
The scope note for the term “heart failure” includes: car-
diac failure, congestive heart failure, decompensation, heart
decompensation, congestive heart failure, left sided heart
failure, left-sided heart failure, right sided heart failure, right-
sided and left sided heart failure, myocardial failure, heart
failure with reduced ejection fraction (HFrEF), heart fail-
ure with preserved ejection fraction (HFpEF). The scope
note for “cardiomyopathy/ies” includes: a group of diseases
in which the dominant feature is the involvement of the
cardiacmuscle itself; cardiomyopathies are classified accord-
ing to their predominant pathophysiological features (dilated
cardiomyopathy, hypertrophic cardiomyopathy, restrictive
cardiomyopathy) or their etiological/pathological factors
alcoholic cardiomyopathy, endocardial fibroelastosis, pri-
mary and secondary cardiomyopathies, primary and sec-
ondary myocardial disease.
The SCOPUS database assigns the following definition
to “machine learning”: a type of artificial intelligence (AI)
that enables computers to independently initiate and exe-
cute learning when exposed to new data. The scope note for
“machine learning” includes: machine learning and trans-
fer learning. Data science is defined as “an interdisciplinary
field involving processes, theories, concepts, tools, and tech-
nologies, that enable the review, analysis, and extraction of
valuable knowledge and information from structured and
unstructured (raw) data” [24,25]. The scope note includes
data analytics, data driven science and data science. A search
limit was applied to include original articles and confer-
ence papers published in English. The titles and abstracts of
full-text articles were screened for suitability after applying
inclusion and exclusion criteria.
4.2 Inclusion and exclusion criteria
Inclusion and exclusion criteria were agreed between clini-
cians and data scientists. Clinicians defined the most relevant
aspects of heart failure (HF) identification, detection and
diagnosis in the context of the application of machine learn-
ing (ML) to electronic health records. Selected studies used
ML techniques to analyseHFdatasets to predict the following
outcomes: worsening of a clinical condition, readmission to
hospital, onset of illness, classification of HF stage accord-
ing to symptoms reported by patients, classification based
on the HF etiology, HF mortality, response to introduced
HF treatment. Included studies were published from 2014
until February 2021 (inclusive). Included studies applied
ML to the range of medical datasets of HF patients, i.e.
electronic health records (EHR), datasets from primary or
secondary care, open access HF data sets and reposito-
ries with data from patients with cardiovascular disease.
We excluded studies whose primary focus was the analy-
sis of: ECG signals of HF patients, echocardiographic video
loops, biobank datasets, image repositories and image signals
from CMR and PET, histology and pathology datasets from
cardiomyopathy cases, the ECG signals and results of the
cardiopulmonary exercise stress test (CPEST), data from car-
diac resynchronisation therapy devices (CRT, CRTP, CRTD),
data exclusively from extra-corporal life support (ECLS) like
blood parameters. Studies were excluded if they exclusively
includedmobile health and telehealth datasets ofHFpatients,
health claim databases and healthcare cost analysis related to
HF cohorts. Studies using natural language processing (NLP)
and text mining techniques as the only means to interrogate
the HF dataset were excluded. We excluded studies which
focused on the analysis of health record access patternswhilst
not analysing the health records themselves. Theses, reviews,
book chapters, editorials, letters, conference abstracts with-
out full text and non-English articles were excluded. A data
extraction table was used to record features of interest from
each study, including study quality indicators. Predefined cri-
teria and its details are listed in a supplementary material.
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Fig. 1 PRISMA flow diagram of the identification process for articles included in this review. PRISMA = preferred reporting items for systematic
reviews and meta-analyses; Adapted From: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. [23]
5 Results
5.1 Common HF problems addressed byML
At the outset of the Results section, it is useful to outline
common issues in HF that require attention of healthcare
providers. For years clinicians have tended to focus upon
providing effective care to HF patients, however the interest
of data scientists to provide solutions to this domain creates
the opportunity to improve HF services by employing ML
to address common HF problems. HF is a complex clinical
syndrome and due to the shear volume of specific problems
associated with this syndrome the inclusion criteria were
employed to narrow the focus of studies to those working
with clinical and administrative HF datasets. This review is
focused upon the ways in which EHR, clinical and adminis-
trative data can reveal correlations within patient data that
inform both research and clinical practice. Therefore this
review will not focus upon studies analysing ML applica-
tion to electrocardiogram (ECG) nor cardiac imaging. The
extensive research into electrocardiogram (ECG) signal pro-
cessing andECG interpretation has been recently synthesised
in the state-of-the-art systematic review of application of
deep learning to the ECG [26]. Somani et al. (2021) provide
an overview of deep learning application to ECGs, its bene-
fits, limitations as well as future areas for improvement [26].
We recognise however that areas of cardiologywhereMLand
AI solutions have been successfully applied to ECG analy-
sis and cardiac imaging which has resulted with the FDA
approval in clinical settings. This is exemplified by soft-
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Table 1 Outcomes examined in the studies included in the literature review. N - number of studies, % out of 81 studies. *Other - modelling of the
response to HF treatment, reduction of HF data dimension
Outcomes of studies N/% Citations to studies
Detection of HF onset 25 (31%) [29–53]
Mortality prediction 20 (26%) [54–73]
Prediction of readmission to hospital 18 (21%) [74–91]
Classification of HF (according to NYHA class or aetiology) or clustering 11 (13%) [92–102]
Other: * 5 (6%) [35,62,103–106]
ware to automated ECG interpretation and reporting, deep
learning enabled heart function analysis of cardiac magnetic
resonance (CMR) images and ECHO imaging [27]. Cardiac
imaging is a broad and well established sub-speciality of
cardiology. As with the case of ECG, we refer readers to
the systematic review by Dey et al. (2019) which provides
insight into AI application to cardiac imaging [28]. Below
we list common problems within the heart failure domain
addressed by ML application to electronic health records:
1. HF detection and diagnosis from electronic health records
or administrative data.
2. Prediction of HF readmission to hospital (30-day, 60-day,
3-month, 6-month readmission since the index hospitali-
sation). Studies within this domain problem focused upon
grouping patients according to the readmission risk. The
search for the accurate prediction of HF readmission is
likely influenced by incentive programs in the USA that
record readmission rates in the annual payment update by
the insurance company Medicare.
3. HF mortality prediction based on patients’ current clin-
ical status, results of routine blood tests (biomarkers),
non-invasive cardiac imaging - echocardiogram (ECHO),
magnetic resonance imaging (MRI), myocardial perfu-
sion scan (MPS) and invasive tests such as cardiac
catheterisation to assess pressures in heart chambers, and
coronary angiogram and intravascular ultrasound (IVUS)
- to assess coronary artery plaque volume and composi-
tion.
4. HF classification applied in line with already known HF
categories, based on patients’ symptoms such as New
York Heart Association (NYHA) and based on the type of
HF derived from international HF guidelines such as clas-
sification according to the functional assessment of left
ventricle by calculating ejection fraction (LVEF). Distinct
types of HF would include HF with reduced EF (HFrEF),
HF with mid range EF (HFmrEF) and HF with preserved
EF (HFpEF).
5. HF classification using unsupervised ML methods in
order to discover new phenotypes of HF patients, not
described today based on the above criteria.
6. Prediction of the outcomes and response to invasive
therapies like implantable cardiac devices: implantable
cardioverter defibrilator (ICD), cardiac resynchronisa-
tion therapy (CRTP/D) and left ventricle assisted devices
(LVAD).
In this review, we grouped studies according to the spe-
cific HF problem which they aimed to address. Based on
this approach we produced a taxonomy of common HF
problems investigated by ML applied to HF datasets. Table
1 presents references to studies grouped according to the
domain problem that they attempt to solve. In Fig. 2, we
present a taxonomy of the common HF problems and which
ML methods were applied to solve those problems.
5.2 General study characteristics: variables, source
and size of datasets used.
All 81 studies were retrospective, observational or cross-
sectional cohort studies. HF datasets comprised a mixture of
continuous and discrete variables. Most studies used either
structured or unstructured data, though some studies inte-
grated both and described it as a novel approach in their data
analytics. Clinical and administrative features were consid-
ered, as listed in Table 2. The most common source of HF
patient data used for analysis in reviewed studies was an
extract from Electronic Health Records (EHR) of large clin-
ical centers, university hospitals, district general hospitals or
community health centers. Several studies used registry data
as in a case of Swedish national cardiovascular registry [55],
acute HF registry enrolling patients from 10 hospitals across
Korea [57], data fromBIOSTAT-CHFproject,which enrolled
patients from 69 centres in 11 European countries between
2010 and 2012 to determine profiles of patients with HF that
do not respond to recommended therapies [59], or as in a
case of Frizell at al. (2017) study dataset was obtained by
linking patients from the “Get With the Guidelines” Heart
Failure registry with Medicare data from 289 hospitals in
USA [79]. Blackstone et al. (2018) [73] aimed to develop
a decision aid to aggregate adverse events in heart trans-
plant and measure end organ function to inform clinical
decision making. They used the Electronic Data Interface
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Fig. 2 Taxonomy of the main
problems within the HF domain.
This Figure presents the
common HF problems and most
commonly used ML algorithms
in addressing these specific HF
domain problems. HF problems
are colour coded and ML
methods used in solving these
problems are colour coded and
listed in order of the most
frequently used method for each
particular domain problem. For
each ML method used in the
specific domain problem, there
is a median AUC provided, with
the performance range
(min-max) achieved by ML
model applied to the specific
problem
for Transplant (EDIT) database, updated by transplant coor-
dinators during the course of clinical care and data from The
Cardiovascular Information Registry (CVIR), a prospective
registry of all cardiovascular procedures performed in Cleve-
land Clinic, Ohio, USA. These data were supplemented with
queries from EHR to resolve inconsistencies and impute the
incomplete data.
Several studies however used open-source cardiovascular
data available from data repositories available in a public
domain. Below we provide the web address to the open-
source cardiovascular data repositories used in papers cited
in this review:
1. Cleveland Clinic FoundationHeart DiseaseData Set from
University of California Irvine (UCI) Machine Learn-
ingRepository available on https://archive.ics.uci.edu/ml/
datasets/heart+disease
2. MIMIC - III Medical InformationMart for Intensive Care
from Beth Israel Deaconess Medical Center in Boston,
Massachusetts available onhttps://github.com/MIT-LCP/
mimic-website
Eleven studies [29–31] [34,37,38,50,84,92,105,107] used
Heart DiseaseData Set from theMLRepository of the Cleve-
land Clinic Foundation and University of California, Irvine
(UCI) [108]. This dataset was used by 8 out of 10 studies
to develop a model to predict the onset of HF. Two studies
developed theHF classificationmodel. Apart fromCleveland
Clinic repository, real-world datasets from Microsoft Azure
research platform [59] were used and the publicly available
MIMIC-III benchmark datasets from critical care databases.
In case of multimodal data, including live and still imag-
ing data and ECG signals, they are often stored on multiple
platforms and due to the nature of the data (coded millions of
pixels of still images, video loops). The process of integrating
this informationwith clinical information readily available in
HER poses a challenge. Patient data are fragmented and scat-
tered across multiple silos, which would require integration
prior to application of advanced data analytics.
In Table 3, we list most commonly used variables utilised
by cited authors in their final models. The most commonly
used variables in mortality prediction models were (in order
of most frequently used) (1) left ventricular ejection fraction
(LVEF), (2) the presence of other clinical conditions (com-
morbidities), (3) age and (4) renal function (as measured by
serum creatinine level). In the group of HF classification into
different types of HF or different stages of HF, the most com-
monly used variables were (1) the presence of hypertension,
(2) age, (3) gender, (4) presence of coronary artery disease,
(5) blood tests (wide range of blood tests), (6) renal function
tests (serum creatinine level and sodium level). In the group
of HF onset prediction, the most commonly used variables
were (1) age, (2) presence of diabetes and (3) hypertension.
The number of variables used across all studies ranged from
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Table 2 Examples of discrete and continuous data used in studies presented in the systematic literature review
Discrete data Continuous data
Demographics Physical examination:
Age / Sex / Gender: Female/ Male Pulse Rate (beats per minute)
Race: White, African American, Hispanic, American
Indian,Native Asian
Respiratory Rate (breath per minute)
Medicare Insurance / Medi-Cal Insurance Systolic Pressure in mmHg
Contacts with Healthcare/Care management: Body Mass Index (BMI)
Discharge to Skilled Nursing Facility Body Surface Area (BSA)
Missed Clinic Visits in Prior Year Blood tests
ED and O/P Visits in Prior Year Biochemistry:
Admission in Previous Year Serum B- Natriuretic Peptide (pg/mL)
In-admission Telemetry Monitoring Glucose (mg/dL),
Clinical data Fasting blood glucose >120 mg/dl
Symptoms: Serum Creatinine (mg/dL)
Types of chest pain, Breathlessness as per NYHA class Urea (mg/dL)
Past Medical History: Serum Albumin (g/dL)
Ischemic Heart Disease Cholesterol level
Previous Myocardial Infarction Serum Sodium and Potassium (mEq/L)
Previous Heart Failure Haematology:
Type of Cardiomyopathy Haemoglobin (g/dL), Haematocrit (%)
Coronary Artery Disease Additional tests
Valvular Heart Disease ECG (recorded at rest) features
Arrhythmias heart rhythm: sinus rhythm atrial fibrillation
Cerebrovascular Disease/Stroke/TIA ORS width - broad or narrow
Vascular/Circulatory Disease Exercise Stress Test (EST):
Diabetes type I and II MPHR - maximum predicted heart rate
Renal Disease or ESRD on Dialysis EST induced angina, ST segment depression,
downslope of ST segment or upslope of ST
segment
Chronic Lung Disease/COPD/Asthma ECHO features
Metastatic Cancer of solid organ or Acute Leukemia LVEF in % (left ventricular Ejection Fraction)
Severe haematological disorder Right ventricular systolic pressure
Liver Disease Pulmonary artery mean pressure
Mental Disorder(s) Chest XRay features:
Medication History Lung fields
Social History: Alcohol Abuse, Drug Abuse, Protein Caloric
Malnutrition, Functional Disabilities
Cardiomegaly
8 to 4205. Figure 4 shows the number of variables used in
models applied to specific outcomes groups. The majority
of authors reported the exact number of variables included
in their model. A small minority provided neither the total
number of variables nor any clear description of the variables
used.
Figure 3 shows themedian size of the patient cohort exam-
ined in studies. The largest patient samples were used in
readmission prediction models with the median sample size
of 5676 (min. 380, max. 93260), followed by mortality pre-
diction models with a median sample size of 5044 (min. 95,
max. 44886), followed by studies focused on classification
of HF with median sample size of 853 (min 162, max 41713)
and the smallest samples were used in HF prediction models
with median sample of 439 (min 46, max 67697).
5.3 Dimensionality of datasets
The healthcare data are highly dimensional. Several studies
reviewed aimed to reduce data dimensionality [50,105] in
order to improve the performance of their algorithm. Models
trained on datasets with many features and limited number
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Table 3 Most commonly used variables and median numbers of variables used in final models in cited studies; all grouped by outcomes of the
studies
Study outcome Median number of variables Most common variables
Detection of HF 14 (range: 13 - 1823) Age, presence of: diabetes,
hypertension
HF mortality prediction 45 (range: 8 - 1302) LVEF, comorbidities, age, renal
function tests (creatinine, urea)
HF classification 55 (range: 11 - 400) Hypertension, age, gender,
coronary artery disease, blood
tests, renal function tests
Prediction of HF readmission 56 (range: 16 - 4205) Age, blood tests, comorbidities

















Fig. 3 Patients’ sample size used in ML studies grouped by examined
outcomes. (On each box, the central mark indicates the median, and the
bottom and top edges of the box indicate the 25th and 75th percentiles,
respectively. The whiskers extend to the most extreme data points con-
sidered outliers, and the outliers are plotted individually using the ’+’
symbol. For better visualisation effect, 3 studies have been removed
from the plot. Studies working on 93260 (HF Readmission), 67697 (HF
Prediction) and 41713 (HF Classification) patients are not included in
the figure.)
of recorded observations for each variable are exposed to a
risk of over-fitting. This leads to a reduction in the model
performance when it is applied to an external dataset. In
Fig. 6 we illustrated the relationship between sample sizes
of all studies and number of variables used. Studies with
sample size less than 10,000 patients achieved median AUC
0.86, whereas studies with sample sizes greater than 10,000
patients achieved median AUC of 0.814. We correlated the
ratio between sample size and the number variables with the
study performance as shown in Fig. 5c. While we would
expect studies with smaller sample sizes to use a fewer num-
ber of variables in order to improve algorithm performance,
we did not observe much consideration of the dimension-
ality aspect in reviewed studies. Surprisingly there was no
correlation observed between the algorithm performance and
sample size to number of variables ratio. Figure 7 shows the


















Fig. 4 Number of variables used in ML studies, grouped by outcomes.
(On each box, the central mark indicates themedian, and the bottom and
top edges of the box indicate the 25th and 75th percentiles, respectively.
Thewhiskers extend to themost extremedata points considered outliers,
and the outliers are plotted individually using the ’+’ symbol. For better
visualisation effect, 4 studieswere removed from this plot. Studies using
4205 (HF Readmission prediction), 1823 (Detection of HF), 1302 (HF
Mortality prediction) and 939 (HF Readmission prediction) variables
in their model.)
ratio of the number of variables to the number of patients
included in the study grouped by the HF problem that they
address.
5.4 Handling of missing data
Most real-world datasets contain missing values. This can
cause issues for a number of ML methods [109]. The per-
centage of missing values differed between studies. In many
cases, the variables with missing values were removed from
the dataset. For example, Sideris et al. (2016) excluded
features corresponding to patient weight from their analy-
sis because 97% of these values were missing [84]. They
also removed information about the medical specialty of the
admitting physician because this information was missing in
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Fig. 5 Representation of the ML model performance in relation to
number of variables used, sample size and the ratio between sample
size and number of variables. a Number of variables used in a study vs
ML model performance. b Sample size used in a study vs ML model
performance. c Ratio of the sample size to the number of variables used
in theML algorithm vsMLmodel performance. Least square regression
line indicates negative correlation between model performance and the
number of variables per patient in the sample cohort (R value 0.03)
49% of cases. Similarly, information about the payer code
was removed from the final dataset, because it was unknown
for 39.5% of patients [84]. For Ahmad at al. (2018), over
20% of missing data for a specific variable was enough
to exclude this variable from the analysis [55]. Accord-
ing to the authors, the most likely missing variables were
laboratory values. They observed an impact on prognosti-
cation and clustering when variables of known prognostic
value were missing, such as B-natriuretic peptide (BNP)
serum levels [55]. Chu et al. (2020) excluded patient sam-
ples with more than 30% of missing values from the analysis
[68]. The Cleveland heart disease dataset contains records
of 303 patients with 76 attributes. From this dataset usually
6 patients are removed in order to perform analysis [29–
31,34,37,38,50,84,84,92,105,107]. Researchers worked on
297 records without any missing values and tended to use
13 key attributes [31]. A variety of approaches were used to




















Sample size and number of variables used in ML studies
A
B
Fig. 6 Scatter plot illustrating sample size used in the ML study and
variables tested in the same study. For better visualisation effect 2 studies
using 4205 and 1823 variables in their model have been removed from
this plot. Studies with smaller sample sizes, less than 10,000 patients
and variable size less than 200 (Cluster A), achieved median AUC 0.86,
whereas studies with sample sizes greater than 10,000 patients and vari-
ables number less than 400 (Cluster B) had median AUC of 0.814. Blue
arrow indicates a study which used 1302 variables. This study used
multi-view ensemble learning based on empirical kernel mapping to
predict HF mortality and achieved AUC of 0.89. Green arrow indicates
a study, that used 939 variables to train neural network model to predict
HF hospital readmission. This model achieved AUC of 0.77



























Fig. 7 Box plots illustrating ratio between sample size and number
of variables used in reviewed studies. (On each box, the central mark
indicates the median, and the bottom and top edges of the box indicate
the 25th and 75th percentiles, respectively. The whiskers extend to the
most extreme data points considered outliers, and the outliers are plotted
individually using the ’+’ symbol.)
input missing data. Schrub et al. (2020) used the SVDimpute
function within the impute package in R to impute the miss-
ing data [100]. They report that the percentage of missing
values ranged from 0% to 28% [100]. Kwon et al. (2019)
in an acute HF mortality model also replaced missing data
using data imputation [57]. They used patients’most recently
recorded values of the missing feature to complete variables
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such as the vital signs, demographics, biochemistry results
or heart scan features that were available in patients’ notes.
Using this method Kwon et al. (2019), created a training
dataset consisting of 12,654 datasets amplified from 2165
patients. As a result, many training datasets were generated
based on data sourced from the records of only one patient. In
the opinion of Kwon et al. (2019) this dataset was sufficient
for developing a deep-learning model to predict HF mortal-
ity [57]. Their deep neural network algorithm achieved an
AUC score of 0.880 [57]. Nonetheless, this model outper-
formed both the American Cardiac Association “Get With
The Guidelines’ (GTWG-HF) risk model and The Meta-
Analysis Global Group in Chronic Heart Failure (MAGGIC)
risk model for predicting 12- and 36-month mortality [57].
5.5 Overview of algorithms
Table 4 presents all ML algorithms that have been employed
within the reviewed studies. Some studies used more than
one ML method; hence, the total number of methods used
is larger than the number of studies included in the liter-
ature review. Most commonly We observed an increase in
the use of deep learning in tackling HF problems. Neural
networks performed very well in predicting HF mortality or
detecting HF from EHR. In the majority of the studies using
neural networks, they outperformed traditional ML methods
[56,68,70,72]. Hence, deep learning (DL) could potentially
improve the accuracy of HF classification, detection, and
outcome prediction. However, DL is typically applied when
using image data (e.g. echocardiograms, CMR, CT) or ECG
data (e.g. usingCNNs orRNNs) but can also be used for other
datasets, including text analysis. Moreover, the problemwith
DL models is that they lack explainability, hence there is
a trade off between accuracy and explainability. Therefore,
the adoption of DL in clinical practice can be challenging
given the need for accountability. Hence, one could argue that
traditional ML could be preferred given that some of these
techniques can provide an insight into the rationale and logic
behind the computer’s recommendation. Nevertheless, there
is ongoing research that is investigating methods to explain
DL models, for example using attention maps [110] which
allow the user to see what features the DL algorithm focused
on just before it produced its classification.
5.6 Algorithms performance
The comparison of algorithmic performance in studies con-
sidered within the review is challenging due to each study’s
performance being reported using variable ML evaluation
metrics. Firstly, studies that used data from heterogeneous
populations and models, have been trained on populations
with different sample distributions and characteristics. Sec-
ondly, studies were set to predict a number of different
outcomes. Thirdly, authors used various numbers of vari-
ables and some authors introduced a features selection
process to identify most accurate predictors to be used in
the final predictive model. The described heterogeneity of
study characteristics prevents us from performing quanti-
tative comparison of achieved performance by reviewed
models. Figure 2 presents a taxonomy of the common HF
problems and provides information on the range of the per-
formance of ML methods applied to the specific problem.
Figure 2 presents a taxonomy of the common HF problems
and provides information on the range of the performance of
ML methods applied to the specific problem. In studies pre-
sented in this review, the authors used various performance
metrics. Area Under the Receiver Operating Characteristics
(AUROC or C-statistic) were the most common; followed by
sensitivity, specificity, accuracy and F1 score. The authors
typically compared their model’s performance to previously
published studies. There was a tendency to point out that
previous models achieved a lesser performance, even when
their model only performed better by a fraction under the
ROC curve. In studies predicting HF onset and detection of
HF, the most commonly used algorithm was random forest
(RF), followed by logistic regression, SVM and decision tree
methods. Best median AUC was achieved by Decision Tree
with median AUC 0.88, followed by RF - median AUC 0.87,
and SVM - median AUC 0.83. Logistic Regression was the
most commonly used method in mortality prediction stud-
ies, followed by RF and deep learning (neural networks).
The highest median AUC was achieved by neural networks
at 0.870, followed by random forest with median AUC of
0.848 and logistic regression with amedian AUC of 0.805. In
studies predicting the readmission to hospital, the most com-
monly used method was deep learning, followed by logistic
regression, SVMandRF.The bestmedianAUCwas achieved
by SVM -medianAUC0.68, followed by logistic regression -
AUC 0.655 and deep learning - AUC 0.619. Various methods
of clustering were used in studies performing the classifica-
tion of HF, i.e. K-means Clustering, K-Nearest Neighbour
method, hierarchical clustering, SVM, decision tree. Despite
the wide use of modern ML methods, logistic regression
was still the most common method used in predictive mod-
els.Nevertheless,MLmodels showed improved performance
over models using traditional statistical methods. In general,
the use of aMLmodels employing variety of additional vari-
ables improve HF mortality risk prediction when compared
with conventional approaches like regression models alone
[65].
5.7 Addressing previous gaps in ML
Research into ML application to HF datasets evolved and
brought some needed solutions to previously identified gaps
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Table 4 Types of Machine
Learning methods used in cited
studies. N (%) number of
models (% out of 81 studies)
ML alghorithms N (%) number of (models
(% out of 81 studies )
Supervised ML methods
Logistic regression (LR) (15) (including Boosted
LR, Regularised LR, Knowledge Driven Scalable
Orthogonal Regression, Spike-and-slab regression,
Multivariable regression, Stepwise LR, Ensemble
LR)
22 (26%)
Decision Tree (including Decision Tree ID3 (10),
Boosted Decision Tree (2), Boosted Regression
Tree (3)
15 (18%)
Random Forest 14 (17%)
Support Vector Machine (SVM) 12 (14%)
Naive Bayes (NB) (including NB (5), Tree
Augmented NB (2), Gaussian NB (1))
8 (9%)
Deep learning
Neural Networks (NN) (including Recurrent NN (7),
Convolutional NN (2), Deep NN (1))
10 (12%)
Unsupervised ML
Clustering Methods (including k nearest neighbour
(6), k-means clustering (3), hierarchical clustering
(1))
9 (11%)
Selection Operator Models 1
Feature Rankin Analysis 1
in ML methods. Below we describe how recent studies
addressed those unmet needs:
1. Using synthetic data. Even though there is still wider need
for improvement of validationmethods, Xiao et al. (2018)
[82] successfully used synthetic data as a validation cohort
in their readmission prediction study. They used synthetic
data as a benchmark for reproducing experimental results.
After generating 3000 synthetic patients, they used syn-
thetic data of 500 patients for validation, and another 500
for testing.
2. Using algorithms to tackle missing data. It has been
noted that the omission of variables with a consider-
able number of missing values should not be a routine
approach inML studies [111]. There has been an increase
in using algorithms to address missing values such as
multiple imputation techniques, rather than ignoring vari-
ables from analysis. Blackstone et al. (2018) [73] used
5-fold multiple imputation using a Markov Chain Monte
Carlo technique to obtain final parameter estimates and a
variance-covariancematrix to dealwithmissing variables.
Mahajan et al. (2017) [78] used multiple imputation by
chained equations re-sampled over five imputed datasets
to fill in missing values for used variables. Jiang et al.
(2019) [83] used simply mean imputation to impute miss-
ing fields of important variables. The above-described
methods of dealing with missing data allowed researchers
to deal with the most difficult aspect of real-world data -
missing values.
3. Feature selection techniques. Another difficult aspect of
real world data - high data dimensionality - was dealt
with successfully, in number of studies. Wang et al. [67]
in their HF mortality prediction systems applied Orthog-
onal Relief (OR) algorithm to remove irrelevant and
redundant features from the dataset. This approach sig-
nificantly reduced the dimensionality of data and allowed
researchers to successfully use the Dynamic Radius
Means classification algorithm to predict mortality from
HF.
4. Improved ML execution time. Haq et al. [29] used fea-
ture selection algorithms in their classification algorithm
and not only the accuracy of the model increased but the
execution time of the diagnosis system was significantly
reduced.
5. Use of ensemble models. In our review we observed a
new trend to use multi-model predictive methods. This
multi-model architecture can provide better accuracy than
best model approach and it has been used successfully
by research groups. Priyanka et al. (2016) [33] and Che-
ung (2018) [76] proposed a novel hybrid model bridging
multi-task deep learning and K-nearest neighbors (KNN)
for individualised treatment outcome estimation in HF
patients. This model achieved F1 score of 0.796 and out-
performed state-of-the-art ML predictive models.
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5.8 ML impact on advancing HF problem-solving
In this review we highlight exemplary work presenting how
MLanddata analysis impactedHFproblem-solving and have
advanced the knowledge in this domain.
1. Personalised medicine. Probably the most important
advancement is an important role of ML in executing
problems of the personalised medicine. Ahmad et al.
(2018) [55], who worked on the SWEDEHeart registry
data, presented potential clinical implications of their HF
clustering study. They concluded that if clustering into
distinctive HF phenotypes was embedded within EHR,
they would ultimately create a self-learning healthcare
system that could suggest a personalised therapy for spe-
cific needs of individual patients [55]. Another good
example is the use of deep learning in identifying the
important factors which increase patient mortality. This
could potentially help clinicians to augment their clinical
decision and review planned interventions for HF patients
[61].
2. Improving clinical trial design. Multiple studies using
ML identified features carrying high predictive value in
HF course, confirming what RCTs in HF with reduced
ejection fraction (HFrEF) showed to date. There is an
opportunity that advance data analytics ofHFdatasetswill
lead to identification of new features in the HF pathol-
ogy, that could be targeted during future clinical trials.
ML based clustering gives unique opportunity to identify
distinct phenogroups of various types of HF, caused by
different etiologies. HF with preserved EF (HFpEF) is a
common type of HF, still poorly understood. Gu et al.
[99] showed that there are 3 distinct cohorts of patients
within a group of patients with HF with preserved ejec-
tion fraction (HFpEF). Those cohorts are characterised
by significant differences in comorbidity burden, underly-
ing cardiac abnormalities, and long-term prognosis. They
observed that beta-blockers or ACEi/ARB therapy was
associated with a lower risk of adverse events in specific
HFpEF phenogroups [99]. Again, this finding should be
explored further and considered for validation in prospec-
tive clinical trials. Ahmad et al. [55] suggested that ML
has a significant role to play in improving clinical trial
design and execution.
3. Healthcare data quality and data integration. Liu et al.
(2019) [91] proposed methodology and process on con-
structing large-scale patient cohorts which allowed to
form the basis for effective clinical case review and
efficient epidemiological analysis of complex medical
conditions. Ben-Asouli et al. (2019) [56] recommended
that policymakers should allocate resources to promote
projects that bring big data analytics closer to clinical
practice. They concluded that there is an opportunity to
improve patients’ outcomes by investing in comprehen-
sive, integrated health IT systems and projects aimed at
simplifying ML to clinical teams [56].
5.9 Authors affiliation and input from clinicians into
ML studies
This review included papers from 514 authors. Of these, 297
authors were affiliated with either computer science, infor-
matics, statistics or a related area. A total of 213 authors
were affiliated with a medical centre and had MD or MBBS
titles. There was an average 3:2 ratio between authors in
reviewed papers in terms of the ratio between IT special-
ists, authors, and medical professional authors. The ratio was
higher when we observed the median number of IT special-
ists to medics - 3:1. There were, however, 24 papers (28%)
that were authored exclusively by IT specialists. Of these,
the authors of only 2 papers consulted cardiologists regarding
issues related to feature extraction [112] and interpretation of
the results that their model achieved [74]. This left 22 papers
(25%) that were exclusively authored by non-clinical teams.
These teams were prone to over-claiming and most impor-
tantly, risked producing flawed predictions. There is one
study where classification criteria and the model results had
not been discussed with clinicians. Despite producing a pre-
dictive model which, from a clinical perspective, incorrectly
classified patients into HF severity groups, the authors still
quoted that the decision tree ID3 model gave better results
than all previously reported models attempting to solve the
classification problem in HF (Accuracy 0.97). Incorrect clas-
sification of a patient to “at risk” groupwhen they should have
been allocated to “critically ill” because the patient was less
than 42 years old and had significantly reduced left ventricu-
lar ejection fraction LVEF <40%. The patient was classified
as “critically ill” when having a normal heart rate of 56 beats
per minute but was aged above 60. This work demonstrates
the importance of close collaboration between data analysts
with domain experts in order to produce a model giving
high quality, clinically appropriate and interpretable results
[35]. Rammal et al. (2018) demonstrates the importance of
utilising clinical expertise [32]. They used MATLAB Haar
wavelets and local binary pattern (LBP) to interpret patients’
chest radiographs [32]. Based on LBP assessment they clas-
sified patients into HF or non HF groups. These radiographs
however were not formally reported by a radiologist con-
sultant. Despite this serious drawback, authors claimed that
their Random Forest based algorithm achieved AUC of 0.94
in the ability to classify to HF or non-HF group, which would
be questionable, given that they used unvalidated set of chest
radiographs to train their model [32].
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6 Discussion
6.1 Engagement with domain experts
We observed that it can be easy to overstate the claims in a
ML study. There was a tendency among the reviewed publi-
cations to overclaim the usefulness and applicability of the
developed models to solve clinical problems. Models that
are both trained and validated using retrospective observa-
tional cohort studies may be more prone to overfitting data
and therefore are less able to generalise to the general pop-
ulation. Randomised clinical trials (RCT) remain the gold
standard in research leading to introduction of new therapies
and procedures in the clinical medicine. The best practice
to test the applicability of the ML model in a clinical set-
ting would be a RCT to test the ML model vs. standard care
in relation to a pre-specified endpoint or outcome measure.
There is a need for a close collaboration between clinicians
and data scientists to prevent the production and deploy-
ment of poor models. The authors should interpret the results
with a clinical team before drawing the conclusion that their
model outperforms previous models in solving the classifi-
cation problem. Choi et al. (2017) [39] mentioned in their
conclusion, that their team “would have benefited from well
established expert medical knowledge” such as specific fea-
tures or medical ontologies when developing their predictive
model for the early detection of HF. This statement left
us wondering if the engagement with medical experts was
an afterthought in the data mining projects, for example
in instances in which the performance of the model does
not meet the authors’ expectations. In this case, the SVM
predictive model achieved an AUC score of 0.74. We felt
that Saqlain et al. (2016) exemplify the pitfalls of the clin-
ician/data scientist knowledge gap particularly well [112].
The authors were exclusively affiliated with an IT depart-
ment, yet they produced a “treatment plan for HF”. On a
closer look, this plan did not follow any of the current interna-
tional guidelines by respected cardiology societies. Despite
this, the authors claimed the model was both highly accurate
and highly useful [112]. Engagement with clinical domain
expertswould provide greater assurance that the correct ques-
tions are asked and ensure that clinically relevant predictive
models are produced.Moore et al. [96] recognised that under-
standing the underlying characteristics of real live clinical
dataset was fundamental to enabling a critical analysis of the
ML results for the sake of clinical and medical relevance.
In order to explain what measures clinicians use to eval-
uate whether ML application fails or not, it is important
to refer to the human learning process. Clinicians, as well
as other domain experts learn by experience and reflection
[113]. In clinical practice, learning by experience is enabled
by exposure to variety of clinical scenarios over the course
of specialist training and this is followed by lifelong learn-
ing as a part of continuous professional development (CPD)
and continuous medical education (CME). Clinicians con-
tinue the learning through progressive reading and reflective
practice [113]. Most importantly, however, doctors use con-
textualisation to refine and confirm clinical diagnosis based
on objective tests, prior experience and specialists’ knowl-
edge of human physiology and pathology. The skill of a quick
recall of learnt facts and contextualisation allows clinicians
to critically appraise the results produced by application of
ML model to clinical datasets. Clinicians also reason using
first principles (e.g. with understanding of fundamental biol-
ogy) which is arguably very different to themachine learning
paradigm.
Whenassessing the results of theMLexperiment analysing
a large dataset, clinician’s first concern will be the accuracy
of the classification or diagnosis and accuracy of suggested
treatment. In evaluating the contributions and the impact of
ML inHFmanagement, clinicianswould always like to know
how relevant and applicable MLmethod is to the outcome of
the individual patient: can the ML method produce a predic-
tion of an event (being hospital admission, adverse reaction
to treatment, worsening of HF symptoms) that can ultimately
alter this individual patient’s outcomes i.e. improve the qual-
ity of life, prolong the life expectancy, reduce the risk ofmajor
event like stroke or myocardial infarct? Hence, clinicians can
focus onoutcomes based assessmentwhich is very important.
The main benefit that clinicians would expect of having the
access to accurate and reliable ML models embedded within
ECRwill be enhancement of safe clinical practice in linewith
the latest evidence-based treatments and modern diagnostic
methods for the benefit of the individual patient. Involving
a clinician early in the data science pipeline is critical. A
clinician will typically evaluate an algorithm by benchmark-
ing the algorithm’s accuracy with the accuracy achieved by
humans (e.g. consultants). This is an important benchmark
that is often missed. Whilst an algorithm may show results
that are statistically significant at the raw data level, if its
accuracy is significantly inferior to humans’ assessment, then
its utility maybe called into question and lack ’clinical sig-
nificance’. Moreover, clinicians will help focus data science
projects on knowledge and understanding as opposed tomere
accuracy measures. For example, a clinician can inspect the
patient cases that were misclassified by the algorithm and
using expertise to understand why those cases were misclas-
sified.
6.2 HF predictionmodels in international guidelines
Despite extensive research into ML applications in HF, these
ML algorithms do not yet feature strongly in international
guidelines. The European Society of Cardiology (ESC), in its
85-page document with Clinical Guidelines for the Diagno-
sis and Treatment ofAcute andChronicHeart Failure (2016),
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dedicates only a short paragraph to ‘predictivemodels’. They
state that precise risk stratification in HF remains challeng-
ing and the clinical applicability of predictive models is
limited [114]. Similarly, the National Institute for Clinical
Excellence (NICE) emphasize the uncertain clinical value
of predictive models [6]. It should be noted, however, that
several of non-ML risk models are widely used in cardi-
ology such as GRACE [115], HEART [116], TIMI [117]
and euroSCORE [118]. Several of these are focused on HF
specifically. ESC HF guidelines (2016) highlighted cases in
cardio-oncology when a risk score for identifying women
with breast cancer may be useful. Women with breast can-
cer are at risk of developing HF during chemotherapy with
trastuzumab and the risk score could prevent catastrophic
side effects of the cardiotoxic chemotherapy [119]. In 2014
however, the ESC recommended using an online calculator
to estimate a patient’s 5-year risk of sudden cardiac death
(SCD) due to theHypertrophicCardiomyopathy (HCM).The
HCM Risk-SCD calculator is used frequently by cardiolo-
gists to identify patients, who are at highest risk for sudden
death secondary to hypertrophic cardiomyopathy, which is
one of the arrhythmogenic cardiomyopathies. The high score
from HCM Risk-SCD identifies patients who would benefit
most from having a prophylactic implantable cardioverter
defibrillator (ICD) fitted as a primary prevention of SCD.
O’Mahony, from St. Bartholomew’s Centre for Inherited
Cardiac Diseases, stressed that the quantification of the indi-
vidual patient’s risk enhances the shared decision-making
process between the clinician and a patient [120]. Choosing
the best treatment option ‘for the patient with the patient’ ful-
fills the ethos of ‘do no harm’, which is quoted as one of the
most important rules for practicing clinicians by the GMC
Good Clinical Practice Guide [121].
7 Gaps and Research opportunity
In this review, we identified clear gaps and areas for devel-
opment in the subject of HF and data analytics. We have
summarised the gaps in the literature and formulated recom-
mendations for future work and further research within this
discipline.
7.1 Clinical pathways
From a clinical perspective, one of the recurrent issues in
the HF cohort is a poor uptake of evidence-based therapies.
Even when effective evidence therapy is available - patients
are not on optimal targeted therapies and opportunities for
optimisingmedications while waiting for clinical reviews are
missed. We are mindful of variability in access to specialists
with HF expertise. To date, there has not been much con-
sideration given to the analysis of clinical processes, clinical
pathways mining and methods of monitoring patient clin-
ical condition and medication uptitration. Despite multiple
studies which consider the prediction of HF readmission to
hospital, early detection of HF, there still remains an unmet
need to ensure that patients are seen early by specialist teams
and start lifesaving and life prolonging treatment as soon as
possible.
7.2 Access tomodern and divers HF databases
There have been significant improvements over the past
two decades in HF pharmacotherapy and device therapy
[3,114,122–125]. It is possible that models developed on
historical data from 1994, for example, may have little prog-
nostic value when applied to the patients with HF in 2021. To
date, the most widely validated mortality prediction model is
the Seattle Heart Failure Model (SHFM). SHFM is a mortal-
ity calculator developed on patients’ data recruited to clinical
trials between 1992 and 1994. SHFM is recommended by
the International Society for Heart and Lung Transplantation
Guidelines as a guide score used prior to left ventricle assisted
device (LVAD) implantation and heart transplantation in a
severe HF [126]. Simpson and McMurray [127] stated that
there is a need for new models that have been designed
using more contemporary cohorts of HF patients. Those
models should includemultiplemeasurements of biomarkers
routinely used in clinical practice. This will allow the devel-
opment of a dynamic predictive model in contrast to a model
which takes into consideration only the single reading of the
biomarker [127].
Another important aspect is the access to diverse HF
datasets. In our review, we noted that nearly all studies
utilised datasets sourced in America, Europe and Asia. There
were no studies which analysed datasets from the African
continent. This poses a risk of producing biased algorithms,
hence we should look for diverse and highly representative
modern cohorts of patients with HF.
7.3 Validation of algorithms
There seem to be frequent issues regarding validation pro-
cedures of ML models on external patient cohorts. There
is a need to improve validation procedures. Validation pro-
cedures were not well described or robust enough to allow
for a fair model comparison in real-world case studies. We
noted that more work needs to be done with respect to the
calibration, external validation, and deployment of predic-
tive models to ensure that they are suitable for clinical use.
One of the barriers or prohibiting factors may be the diffi-
culty in getting access to external, not seen before healthcare
data. Patient data are governed by data curators and access to
confidential patient information is decided by regulators and
ethical panels. Data governance processes are rigorous and
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lengthy. Validation of the models on real data sets is however
needed to support the credibility and replicability of the HF
models. Once those aspects of ML application to healthcare
data are addressed, there is a chance that wider clinical teams
will start implementing ML models and warm up to the idea
of using decision support tools (DSS) in their clinical routine.
We agree with Kelly et al. (2019) [128] that in order to make
fair comparisons, algorithms should be subjected to a com-
parison on the same external test set that is representative of
the target population, using the same performance metrics.
The external validation could allow clinicians to determine
the best algorithm for their patients.
7.4 MLmethods of the future
To be able to address the issue of model transparency and
external validation, increased effort is required to develop
accessible ML algorithms. The idea of using in clinical set-
tings a method based on a “black box” mechanism will be
quickly rejected by regulators and clinicians, hence there
should be more focus on developing methods which explain
and define how the “black box” operates. Another aspect that
future methods should focus upon is the security and privacy
protections of accessed data. Methods allowing data analysis
at the point of data source to ensure that patients confiden-
tiality is not breached would be an advantage. There is a need
for new ML methods which allow the automation of patient
data capture. ML methods that are going to be deployed and
act as decision support systems should access high quality
data. Automation of data capture eliminates human error and
reduces the burden of administrative tasks which place a bur-
den on themedical workforce. The time spent on data capture
and ensuring high data quality is the time, that is ultimately
taken away from the clinician - patient interaction.MLmeth-
ods that will allow clinicians to work smarter will be in high
demand, especially now, when the clinical workforce can not
work any harder.
7.5 Collaboration with data curators and clinicians
Engagement with clinicians is needed at the very early stages
of data analytics to minimise time spent on investigating
inappropriate questions (from a clinical point of view) and to
increase the utility of proposedmodels in the real world. Col-
laboration with data curators may lead to the development
of data repositories that could serve as external validation
sets for studies performed on different cohort of patients.
Another benefit of access to population-based registries and
healthcare data repositories is the opportunity to run registry
based randomised controlled trials. Registry-based trials are
inexpensive and less time consuming in comparison to RCT
with human participants. Uncomplicated procedures around
safe access to high quality data repositories will promote
data driven research and prompt identification of previously
undetected clinical problems.
7.6 Transparency and reporting of trials with use of
ML
With an increasing number of clinical trials with ML and
AI tools there is understandably an urgent need for transpar-
ent reporting of these trials. ML algorithms and validation
methodologies should be carefully designed and reported
to avoid research waste. CONSORT-AI and SPIRIT-AI
Extension groups will address the issue of transparent and
systematic reporting of trials with ML and AI [129]. In July
2019, there were 368 clinical trials in the field of AI or ML
registered on ClinicalTrials.gov [129]. To date, the majority
of trials were retrospective or observational, with a hand-
ful of prospective trials using AI or ML in an intervention
arm [130]. We noted that the reporting of the studies varied
between papers. Unfortunately, because authors of reviewed
papers did not use a standard set of data and there was
no unified definition for used variables, it was not possi-
ble to create a universal feature dictionary to perform further
data synthesis or comprehensive meta-analysis. This high-
lights the importance of the use of recognised dictionaries
for data collection akin to the standard sets developed by
the International Consortium for Health OutcomesMeasure-
ment [131]. Health Data Research UK (HDRUK) published
the 20 critical questions on transparency, replicability, ethics,
and effectiveness (TREE) on best practice guidance on ML
and AI research for patient benefit [132]. TREE provides a
framework for researchers to inform the design, conduct, and
reporting; for clinicians and policy makers, it helps to criti-
cally appraise where the new findings may be delivered for
the benefit of the patient [132].
7.7 High time for RCTs
The most important gap that has not been addressed as yet
is the lack of evidence that ML driven methodologies could
be used in parallel with everyday standard clinical practice.
Decision support tools based on predictive models, could
save time and money spent in healthcare. We need robust
evidence that ML methods can handle complexities of clini-
cal reasoning before they can be safely deployed to clinical
practice. Developers of predictive models should now move
from the development stage to the deployment stage. As in
a case of patient-specific predictions about HF readmission,
they have not been widely used because of low evidence and
uncertainty about the efficacy and accuracy of using mea-
sures of risk to guide clinical decisions.
Only after proving safety and positive impact on patients’
outcomes could ML and AI tools be deployed to real clinical
environments. The UK Medicines and Healthcare products
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Regulatory Agency (MHRA) considers AI to be a medical
device [133]. MHRA developed a work program to ensure
that AI used for screening, diagnosis, treatment, and man-
agement of chronic conditions is treated as a medical device
and is appropriately evidenced. Main areas of concern are
issues of human interpretability (mentioned earlier “black
box” effect and lack of transparency of AI) and adaptivity
(retraining of AI models in real time). Given that AI and
ML are considered a medical device, they should be tested
under the same rigorous conditions as all implantable and
non-implantable medical devices during prospective RCTs.
Carefully designed RCTs with ML support decision tools
and predictive models in an intervention arm vs standard
of practice would allow objective and robust test of their
effectiveness and impact on clinical practice and patients’
outcomes. The next step should be careful planning of RCTs
where ML guided practice could be compared to standard
of care with clearly defined outcome measures like safety,
improvement of diagnostic process in terms of time from
presentation to diagnosis, accuracy of classification to treat-
ment groups, improvement in time where target medication
doses are achieved.
8 Conclusions
In conclusions, the choice of a 6-year window for the liter-
ature review could be considered a drawback to this study,
however it should be noted that we had the intention to review
ML models which were applied to contemporary cohorts
of patients, who were treated with modern evidence based
HF pharmacotherapy and whose clinical course was closely
monitored by biomarker assays such as proBNP and Tro-
ponin [127]. Even though the review focused on studies from
the last 6 years, it was observed that many research groups
still used rather outdated open source cardiac dataset from
UCIwhichwas donated byDrDavidW.Aha in January 1988.
This database contains data from exercise stress test (EST)
which has been phased out in 2016 as a first line diagnostic
test for patients presentingwith the newonset chest pain from
theUKClinical Guidelines number 95 published byNational
Institute for Clinical Excellence (NICE) [134]. Our review is
limited by our literature search, where we explicitly required
the search terms “heart failure”, “machine learning” or “data
mining” or “data analytics” or “data science” mentioned in
the title or the abstract.
We have excluded studies using datasets from clinical
trials. Data from clinical trials represent a highly selective
cohort of the HF population. The trial data do not repre-
sent real-world healthcare data issues with missing values or
an uneven distribution of features. Due to the differences
in type of data presented in mobile health and telehealth
datasets, we decided to exclude studies focusing on appli-
cation of ML on these datasets. We recognise however the
growing application of wearable technology in collecting
data from ambulatory patients with HF [135]. Whilst we
excluded papers that involve natural language processing
(NLP) techniques as the means of interrogating HF datasets,
we recognise that NLP techniques can be used to analyse
clinicians’ free text notes [136,137].
One of the more significant findings to emerge from this
review is the fact that modern ML models have the potential
to capture the complex interplay between clinical variables
more effectively when compared to traditional statistical
methods. This increases as the sophistication of the models
increases. For example, in the extremely challenging field
of natural language processing, the GPT-3 neural network
has succeeded in learning latent space representations that
allow it to communicate with unnerving ‘human-ness’. How-
ever, the predictive power of ML models tends to correlate
inversely with how explainable they are. To conclude, this
presents a substantial barrier to clinical adoption and more
research is needed to address the transparency and explain-
ability of ML models. Based on our systematic literature
review, we share the conclusions drawn by Di Tanna et al.
(2020) [138] who concluded that despite 40 new publications
on predicting risk in HF being published between 2013 and
2018, there was little evidence to show that any of 58 models
described in those studies have been adopted by healthcare
institutions [138]. We support their observation that there
is no international or local guidance recommending one risk
predictionmodel over another. EvenwhenAmericanCollege
of Cardiology, European Society of Cardiology, or NICE
guidelines mention the use of predictive models, they still
claim that more research needs to be done into the clinical
use of predictive models [3,6,126,139].
The authors of this review paper include clinicians with
significant expertise in HF. Clinical expertise and domain
knowledge facilitated the identification of inaccuracies and
incorrect classifications in context of some studies presented
in this paper. In addition, the findings of this review suggest
that based on the ratio of clinicians to data researchers in
the make-up of authors, good proportion of reviewed studies
were driven by data analysts. It is important to stress that
studies developing predictive models that are to be used in
clinical settings should be co-driven by domain experts via
a very close collaboration with data analysts. This approach
will guarantee that the right research questions are asked at
the right time and promote uptake.
Otherwise there is a risk of producing ML and AI algo-
rithms which will never see the artificial light of a clinical
room. In summary, we see growing potential for ML appli-
cation in routine clinical practice, this however requires a
shift from development stage to the deployment stage of ML
models after validation in RCTs, research into clinical path-
ways, access to modern HF datasets and concerted effort to
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improve transparency and reporting of trials with the use of
ML.
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